Outlook Therapeutics
OTLK
87 hedge funds and large institutions have $11.8M invested in Outlook Therapeutics in 2023 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 12 closing their positions.
93% more capital invested
Capital invested by funds: $6.11M → $11.8M (+$5.66M)
67% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 15
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
7% more funds holding
Funds holding: 81 → 87 (+6)
0.04% more ownership
Funds ownership: 0.53% → 0.57% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$411K |
| 2 |
Morgan Stanley
New York
|
+$152K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$117K |
| 4 |
Millennium Management
New York
|
+$116K |
| 5 |
Barclays
London,
United Kingdom
|
+$79.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$184K |
| 2 |
LNC
Lincoln National Corp
Radnor,
Pennsylvania
|
-$109K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$57K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$25.4K |
| 5 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
-$23K |
OTLK Hedge Fund Activity: Q4 2023 in Review
87 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2023, worth a combined $11.8M — up 93% from $6.11M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new OTLK positions and 12 closed out — a net gain of 6 holders — while 25 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $411K. The largest seller was BNP Paribas Financial Markets, cutting an estimated $184K.
- 87 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2023, up from 81 in Q3 2023.
- Funds reported $11.8M of Outlook Therapeutics stock for Q4 2023, up 93% quarter-over-quarter.
- 18 funds opened new Outlook Therapeutics positions in Q4 2023 and 12 closed out, a net change of +6 holders.
- The largest Outlook Therapeutics buyer in Q4 2023 was BlackRock, an estimated $411K added.
- The largest Outlook Therapeutics seller in Q4 2023 was BNP Paribas Financial Markets, an estimated $184K sold.
Based on aggregated 13F filings for Q4 2023.